PHAXIAM Therapeutics
Jonathan Blachier currently serves as an R&D Project Manager at Phaxiam Therapeutics since June 2023. Prior to this role, Jonathan held the position of R&D Project Manager at ERYTECH Pharma from March 2018 to March 2024 and gained experience as an Assistant de recherche. Jonathan's early career included various positions in R&D, such as Assistant ingénieur R&D at Centre de Recherche en Cancérologie de Lyon, BliNK Biomedical, and NETRIS Pharma, as well as a Technicien de laboratoire at Centre de Recherche en Cancerologie de Lyon. Jonathan's educational background includes a Master in Cancer with a focus on therapeutic innovation in oncology from Université Claude Bernard Lyon 1 in 2019 and a BTS in Biochemistry from Lycée Saint Denis, Annonay, completed in 2005.
PHAXIAM Therapeutics
PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach based on the use of phages, natural bacterial-killing viruses. PHAXIAM is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. PHAXIAM is listed on the Nasdaq Capital Market in the United States (ticker: PHXM) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: PHXM). PHAXIAM is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.